



For more information:
Consuelo Trillo Díaz
ctrillo@rovi.es
Tel: + 34 91 244 44 10

Grant of partially reimbursable aid for the assessment of toxicity in Risperidone ISM® Quarterly

Madrid -January 28, 2022

Last May, ROVI signed a financing agreement with the Centre for Industrial Technological Development (CDTI) to support its research and development work, through the granting of partially reimbursable aid co-financed by the European Regional Development Fund (ERDF) through the Multi-Regional Operational Programme for Intelligent Growth. This programme is included in the framework of the Investment in Growth and Employment objective, in its Priority Axis 01 (Strengthening research, technological development and innovation) and Specific Objective 1.1.2 (Strengthening R & D institutions and creation, consolidation and improvement of scientific and technological infrastructures).

The funding received is intended for the implementation of R&D& I activities within the framework of the project "Evaluation of chronic toxicity in Risperidone ISM® Quarterly", with file number IDI-20220026.

ISM® technology is the exclusive property of ROVI and is internationally patented until 2033. ISM® has been designed by ROVI to overcome most of the drawbacks of extended release oral or parenteral formulations, and consequently has significant technical advantages such as versatility in administration, high encapsulation efficacy of the active ingredient, stability of the biodegradable matrix formed, or greater control over initial drug release by offering clinically significant release profiles from day one, among others. Within this area is where this new project aimed at the evaluation of toxicity in Risperidone ISM®Quarterly is framed.



About

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in 58 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its in-house developed enoxaparin biosimilar in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.